Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6047959 | 0.85 | SIGMAR1 (0.44) | CYP1A2SIGMAR1CHRM5ADRA2C | |
| SCHEMBL30115021 | 0.84 | HRH3 (0.54) | CYP1A2SIGMAR1CHRM5ADRA2CHRH3 | |
| SCHEMBL5467402 | 0.84 | CYP1A2 (0.48) | CYP1A2SIGMAR1CHRM5ADRA2CHRH3 | |
| SCHEMBL30115019 | 0.84 | HRH3 (0.54) | CYP1A2SIGMAR1CHRM5ADRA2CHRH3 | |
| SCHEMBL11841456 | 0.79 | SIGMAR1 (0.50) | CYP1A2SIGMAR1CHRM5ADRA2CMAPT | |
| SCHEMBL12359572 | 0.79 | SIGMAR1 (0.50) | CYP1A2SIGMAR1HRH3 | |
| SCHEMBL12130736 | 0.77 | HRH3 (0.58) | CYP1A2SIGMAR1CHRM5ADRA2CHRH3 | |
| SCHEMBL24008596 | 0.77 | HRH3 (0.42) | CYP1A2SIGMAR1HRH3 | |
| SCHEMBL2769012 | 0.77 | RAD52 (0.51) | CYP1A2SIGMAR1CHRM5 | |
| SCHEMBL30115022 | 0.77 | HSD11B1 (0.54) | CYP1A2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7081557-B2 | Method for the oligomerization of olefins using a cycloalkylalkyl-substituted triazacyclohexane | BASELL POLYOLEFINE GMBH (DE) | 2006-07-25 | — | — | US | disclosed |
| EP-1483051-B1 | METHOD FOR THE OLIGOMERIZATION OF OLEFINS USING A CYCLOALKYLALKYL-SUBSTITUTED TRIAZACYCLOHEXANE | BASELL POLYOLEFINE GMBH (DE) | 2005-12-14 | — | — | EP | disclosed |
| US-20050256357-A1 | Method for the oligomerization of olefins using a cycloalkylalkyl-substituted triazacyclohexane | BASELL POLYOLEFINE GMBH (DE) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256357-A1 | Method for the oligomerization of olefins using a cycloalkylalkyl-substituted triazacyclohexane | ALOX12, ALOX15B, ALOX15 | CYP1A2 1135/4885SIGMAR1 1941/4885CHRM5 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.